Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes

Abstract

Small-dense LDL (SD-LDL) has been particularly implicated in atherosclerosis. It has previously been reported that in non-diabetic people SD-LDL is preferentially glycated. The distribution of glycated apolipoprotein B (glyc-apoB) in lipoproteins in metabolic syndrome (MS) and in type 2 diabetes has not previously been studied.

Plasma apoB and glyc-apoB were determined in different apoB-containing lipoproteins including buoyant and SD-LDL in MS (n=18) and type 2 diabetes (DM) [n=48; 12 statin-untreated (DM−S) and 36 statin-treated (DM+S)].

Plasma glyc-apoB was 5.6 ± 0.9, 3.5 ± 0.5 and 4.0 ± 0.2 mg/dl in DM−S, DM+S and MS, respectively. The glycated proportion of SD-LDL-apoB was greater than buoyant LDL in all groups. SD-LDL contributed most to plasma glyc-apoB in DM−S, because SD-LDL-apoB was higher in DM−S than in MS and DM+S (p < 0.001). Plasma glyc-apoB correlated with SD-LDL-apoB (r=0.74, p < 0.0001 in diabetes and r=0.53, p < 0.001 in MS), but not with HbA_1c.

SD-LDL is preferentially glycated in type 2 diabetes and MS. Its concentration is a stronger determinant of plasma glycapoB than glycaemia. Statin-induced changes in its level may be important in decreasing apoB glycation in diabetes. These findings may explain the small effect of improving glycaemia relative to statin treatment in reducing atherosclerosis risk in type 2 diabetes and the increased risk in MS even before the onset of type 2 diabetes.

Keywords

Glycaemic control glycation metabolic syndrome small-dense LDL statin type 2 diabetes

References

Witztum JL and Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785-1792.

Steinberg D. , Parthasarathy S. , Carew TE , Khoo JC and Witztum JL Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924.

Steinbrecher UP , Lougheed M. , Kwan WC and Dirks M. Recognition of oxidized low density lipoprotein by the scavenger receptor of macrophages results from derivatization of apolipoprotein B by products of fatty acid peroxidation. J Biol Chem 1989; 264: 15216-15223.

Vivekananthan DP , Penn MS , Sapp SK , Hsu A. and Topol EJ Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003; 361: 2017-2023.

Kris-Etherton PM , Lichtenstein AH , Howard BV , Steinberg D. and Witztum JL Antioxidant vitamin supplements and cardiovascular disease. Circulation 2004; 110: 637-641.

Younis N. , Sharma R. , Soran H. , Charlton-Menys V. , Elseweidy M. and Durrington PN Glycation as an atherogenic modification of LDL. Curr Opin Lipidol 2008; 19: 378-384.

Brown BE , Rashid I. , van Reyk DM and Davies MJ Glycation of low-density lipoprotein results in the time-dependent accumulation of cholesteryl esters and apolipoprotein B-100 protein in primary human monocyte-derived macrophages. FEBS J 2007; 274: 1530-1541.

Younis N. , Charlton-Menys V. , Sharma R. , Soran H. and Durrington PN Glycation of LDL in non-diabetic people: Small dense LDL is preferentially glycated both in vivo and in vitro. Atherosclerosis 2009; 202: 162-168.

Tames FJ , Mackness MI , Arrol S. , Laing I. and Durrington PN Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects. Atherosclerosis 1992; 93: 237-244.

10.

Younis N. , Soran H. and Hassanein M. Cardiovascular disease and intensive glucose lowering in type 2 diabetes. QJM 2009; 102: 293-296.

11.

Patel A. , MacMahon S. , Chalmers J. , Neal B. , Billot L. , Woodward M. , et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.

12.

Gerstein HC , Miller ME , Byington RP , Goff DC, Jr. , Bigger JT , Buse JB , et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.

13.

Kearney PM , Blackwell L. , Collins R. , Keech A. , Simes J. , Peto R. , et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-125.

14.

Galassi A. , Reynolds K. and He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006; 119: 812-819.

15.

Bahadir MA , Oguz A. , Uzunlulu M. and Bahadir O. Effects of different statin treatments on small dense low-density lipoprotein in patients with metabolic syndrome. J Atheroscler Thromb 2009; 16: 684-690.

16.

Raal FJ Pathogenesis and management of the dyslipidemia of the metabolic syndrome . Metab Syndr Relat Disord 2009; 7: 83-88.

17.

Therond P. Catabolism of lipoproteins and metabolic syndrome. Curr Opin Clin Nutr Metab Care 2009; 12: 366-371.

18.

World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. http://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf (2006, accessed 25 January 2010).

19.

Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-2497.

20.

Havel RJ , Eder HA and Bragdon JH The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-1353.

21.

Shea EA and Cohen MP Immunologic detection and measurement of glycated apolipoprotein B with site specific monoclonal antibodies. J Immunol Methods 1993; 162: 85-95.

22.

Kruth HS Macrophage foam cells and atherosclerosis. Front Biosci 2001; 6: D429-455.

23.

Shen CM , Mao SJ , Huang GS , Yang PC and Chu RM Stimulation of smooth muscle cell proliferation by ox-LDLand acetyl LDL-induced macrophage-derived foam cells. Life Sci 2001 ; 70: 443-452.

24.

Stocker R. and Keaney JF, Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-1478.

25.

Brown BE , Dean RT and Davies MJ Glycation of low-density lipoproteins by methylglyoxal and glycolaldehyde gives rise to the in vitro formation of lipid-laden cells. Diabetologia 2005; 48: 361-369.

26.

Steinberg D. and Witztum JL

Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis?

Circulation 2002; 105: 2107-2111.

27.

Tsimikas S. and Witztum JL Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk. Circulation 2001; 103: 1930-1932.

28.

Akanji AO , Abdella N. and Mojiminiyi OA Determinants of glycated LDL levels in nondiabetic and diabetic hyperlipidaemic patients in Kuwait. Clin Chim Acta 2002; 317: 171-176.

29.

Malik S. , Wong ND , Franklin SS , Kamath TV , L’Italien GJ , Pio JR , et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults . Circulation 2004; 110: 1245-1250.

30.

Panteghini M. , Cimino A. , Pagani F. and Girelli A. Nonenzymic glycation of apolipoprotein B in patients with insulin- and noninsulin-dependent diabetes mellitus. Clin Biochem 1995; 28: 587-592.

31.

De Michele G. , Correale M. , De Michele O. , Guerra V. , Mazzarelli R. and Misciagna G. Evaluation of serum biomarkers in nutritional disorders: glycated apolipoprotein B, fasting serum glucose, fructosamine, stable and labile glycated hemoglobin in diabetic and non-diabetic subjects . Immunopharmacol Immunotoxicol 2008; 30: 925-936.

32.

Kobayashi K. , Ogasahara N. , Sakoguchi T. , Taishi K. , Makimura H. and Matsuoka A. Correlation between glycated lipoproteins and fructosamine level in serum. Chem Pharm Bull ( Tokyo) 1991; 39: 2149-2151.

33.

Lee W. , Min WK , Chun S. , Jang S. , Kim JQ , Lee DH , et al. Low-density lipoprotein subclass and its correlating factors in diabetics. Clin Biochem 2003; 36: 657-661.

34.

Beisswenger PJ , Howell SK , Touchette AD , Lal S. and Szwergold BS Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 1999; 48: 198-202.

35.

Sattar N.

The metabolic syndrome: should current criteria influence clinical practice?

Curr Opin Lipidol 2006; 17: 404-411.

36.

Malmstrom R. , Packard CJ , Caslake M. , Bedford D. , Stewart P. , Yki-Järvinen H. , et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 1997; 40: 454-462.

37.

Adiels M. , Boren J. , Caslake MJ , Stewart P. , Soro A. , Westerbacka J. , et al. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2005; 25: 1697-1703.